Management

Tromp, M., Eijsden, M. van, Ravelli, A.C.J. & Bonsel, G.J. (2009).Anonymous non-respinse analysis in the ABCD cohort study enabled byprobabilistic record linkage. Paediatric and Perinatal Epidemiology, 23,264-272.Tromp, M., Eskes, M, Reitsma, J.B., Erwich, J.J.H.M., Brouwers, H.A.A.,Rijninks, G.C., Bonsel, G.J. & Ravelli, A.C.J. (2009). Regional perinatalmortality differences in the Netherlands; care is the question. BMCPublic Health, 9(102), 1-9.Uiters, E., Deville, W., Foets, M.M.E., Spreeuwenberg, P.M. &Groenewegen, P.P. (2009). Differences between immigrant and nonimmigrantgroups in the use of primay medical care; a systematicreview. BMC Health Services Research, 9(76), 1-10.Utens, C.M.A., Goossens, L.M.A., Smeenk, F.W.J.M., Schayck, C.P. van,Litsenburg, W. van, Janssen, A., Vliet, M. van, Seezink, W., Demunck,D.R.A.J., Pas, B. van de, Bruijn, P.J. de, Pouw, A. van der, Retera,J.M.A.M., Laat-Bierings, P. de, Eijsden, L. van, Braken, M., Eijsermans,R. & Rutten - van Mölken, M.P.M.H. (2010). Effectiveness and costeffectivenessof early assisted discharge for Chronic ObstructivePumonary Disease exacerbations: the design of a randomisedcontrolled trial. BMC Public Health, 10(618), 1-12.Uyl-de Groot, C.A., Senft, A., Bree, R. de, Leemans, R. & Hoekstra, O.S.(2010). Chest CT and Whole-Body 18F-FDG PET Are Cost-Effective inScreening for Distant Metastases in Head and Neck Cancer Patients.Journal of Nuclear Medicine, 51(2), 176-182.Uyl-de Groot, C.A., Groot, S. de & Steenhoek, A. (2010). The economicsof improved cancer survival rates: better outcomes, higher costs. Ex pertreview of pharmacoeconomics & outcomes research, 10(3), 283-292.Vehmeijer, J.T., Christiaans, I., Langen, I.M. van, Birnie, E., Bonsel, G.J.,Smets, E.M.A. & Wilde, A.A.M. (2009). Risk stratification for suddencardiac death in hypertrophic cardiomyopathy: Dutch cardiologists andthe care of mutation carriers. Netherlands Heart Journal, 17(12), 464-469.Vemer, P. & Rutten-van Mölken, M.P.M.H. (2010). Crossing Borders:Factors Affecting Differences in Cost-Effectiveness of SmokingCessation Interventions between European Countries. Value in Health,13(2), 230-241.Vemer, P., Rutten-van Mölken, M.P.M.H., Kaper, J., Hoogenveen, R.T.,Schayck, C.P. van & Feenstra, T.L. (2010). If you try to stop smoking,should we pay for it? The cost-utility of reimbursing smoking cessationsupport in the Netherlands. Addiction, 105, 1088-1097.Verhoef, T.I., Redekop, W.K., Darba, J., Geitona, M., Hughes, D.A.,Siebert, U., Boer, A. de & Maitland-van der Zee, A.H. (2010). Asystematic review of cost-effectiveness analyses of pharmacogeneticguideddosing in treatment with coumarin derivates.Pharmacogenomics, 11(7), 989-1002.81